Pyruvate kinase activators as a therapy target: a patent review 2011-2017

References

• Warburg O. The metabolism of carcinoma cells. J Cancer Res. 1925;9(1):148–163.
   Google Scholar
• Warburg O, Posener K, Negelein E. Über den stoffwechsel der carcinomzelle. Biochem Z. 1924;152:309–344.
   Google Scholar
• Liberti MV, Locasale JW. The warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211–218.
   PubMed Web of Science ®Google Scholar
• Mazurek S, Boschek C, Eigenbrodt E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr. 1997;29:315–330.
   PubMed Web of Science ®Google Scholar
• Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703–707.
   PubMed Web of Science ®Google Scholar
• Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230–233.
   PubMed Web of Science ®Google Scholar
• Eigenbrodt E, Glossmann H. Glycolysis—one of the keys to cancer? Trends Pharmacol Sci. 1980;1:240–245.
   Web of Science ®Google Scholar
• Kim JW, Gardner LB, Dang CV. Oncogenic alterations of metabolism and the Warburg effect. Drug Discov Today: Dis Mech. 2005;2:233–238.
   Google Scholar
• Chaneton B, Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci. 2012;37:309–316.
   PubMed Web of Science ®Google Scholar
• Iqbal MA, Gupta V, Gopinath P, et al. Pyruvate kinase M2 and cancer: an updated assessment. FEBS Lett. 2014;588:2685–2692.
   PubMed Web of Science ®Google Scholar
• Noguchi T, Yamada K, Inoue H, et al. The L-and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J Biol Chem. 1987;262:14366–14371.
   PubMed Web of Science ®Google Scholar
• Noguchi T, Inoue H, Tanaka T. The M1-and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem. 1986;261:13807–13812.
   PubMed Web of Science ®Google Scholar
• Israelsen WJ, Vander Heiden MG. Pyruvate kinase: function, regulation and role in cancer. 2015: publisher. Semin Cell Dev Biol. 2015;43:43–51.
   PubMed Web of Science ®Google Scholar
• Eigenbrodt E, Leib S, Krămer W, et al. Structural and kinetic differences between the M2 type pyruvate kinases from lung and various tumors. Biomed Biochim Acta. 1983;42:S278–S282.
   PubMedGoogle Scholar
• Strandholm JJ, Dyson RD, Cardenas JM. Bovine pyruvate kinase isozymes and hybrid isozymes: electrophoretic studies and tissue distribution. Arch Biochem Biophys. 1976;173:125–131.
   PubMed Web of Science ®Google Scholar
• Luo W, Semenza GL. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab. 2012;23:560–566.
   PubMed Web of Science ®Google Scholar
• Wong N, De Melo J, Tang D. PKM2, a central point of regulation in cancer metabolism. Int J Cell Biol. 2013;2013:242513.
   PubMedGoogle Scholar
• Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci. 2011;108:4129–4134.
   PubMed Web of Science ®Google Scholar
• Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res. 2012;18(20):5554-61
   Google Scholar
• Mazurek S, Boschek CB, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15(4):300–308.
   PubMed Web of Science ®Google Scholar
• Luo W, Semenza GL. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget. 2011;2:551.
   PubMed Web of Science ®Google Scholar
• Mazurek S, Grimm H, Boschek C, et al. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr. 2002;87:S23–SS9.
   PubMed Web of Science ®Google Scholar
• Anastasiou D, Poulogiannis G, Asara JM, et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science. 2011;334:1278–1283.
   PubMed Web of Science ®Google Scholar
• Boxer MB, Jiang JK, Vander Heiden MG, et al. Evaluation of substituted N,N′-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J Med Chem. 2010;53:1048–1055.
   PubMed Web of Science ®Google Scholar
• Jiang J, Boxer MB, Vander Heiden MG, et al. Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett. 2010;20:3387–3393.
   PubMed Web of Science ®Google Scholar
• Walsh MJ, Brimacombe KR, Veith H, et al. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett. 2011;21:6322–6327.
   PubMed Web of Science ®Google Scholar
• Yacovan A, Ozeri R, Kehat T, et al. 1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett. 2012;22:6460–6468.
   PubMed Web of Science ®Google Scholar
• Swanson MG, Zektzer AS, Tabatabai ZL, et al. Quantitative analysis of prostate metabolites using 1H HR‐MAS spectroscopy. Magn Reson Med. 2006;55:1257–1264.
   PubMed Web of Science ®Google Scholar
• Tessem MB, Swanson MG, Keshari KR, et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR‐MAS spectroscopy of biopsy tissues. Magn Reson Med. 2008;60:510–516.
   PubMed Web of Science ®Google Scholar
• Kung C, Hixon J, Choe S, et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol. 2012;19:1187–1198.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu B, Wu XY, et al. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds. Bioorgan Med Chem. 2015;23:4815–4823.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Park YS, Kim ND, et al. A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia. Mol Cells. 2015;38:373–379.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu XH, Saunders M, et al. Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2). Bioorg Med Chem Lett. 2014;24:515–519.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Yasumatsu I, Asahi T, et al. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator. Bioorg Med Chem. 2017;25:3540–3546.
   PubMed Web of Science ®Google Scholar
• Guo CX, Linton A, Jalaie M, et al. Discovery of 2-((1H-benzo[d]imidazol-1-yl) methyl)-4H-pyrido [1,2-a]pyrimidin-4-ones as novel PKM2 activators. Bioorg Med Chem Lett. 2013;23:3358–3363.
   PubMed Web of Science ®Google Scholar
• Aslan E, Adem S. In vitro effects of some flavones on human pyruvate kinase isoenzyme M2. J Biochem Mol Toxicol. 2015;29:109–113.
   PubMed Web of Science ®Google Scholar
• Aslan E, Guler C, Adem S. In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2. J Enzyme Inhib Med Chem. 2016;31:314–317.
   PubMed Web of Science ®Google Scholar
• Adem S, Aslan A, Ahmed I, et al. Inhibitory and activating effects of some flavonoid derivatives on human pyruvate kinase isoenzyme M2. Archiv Der Pharmazie. 2016;349:132–136.
   PubMed Web of Science ®Google Scholar
• Harris I, McCracken S, Mak TW. PKM2: a gatekeeper between growth and survival. Cell Res. 2012;22:447–449.
   PubMed Web of Science ®Google Scholar